VF00102 / Vitrogro as a pain killer, page-4

Sorry for the corrector that sometime changes my words. But I believe that you all got the points.

We have to change our aims on the product to have in the end our product available on the market as a pain killer. The safe use of one purpose, could lead us to a better understanding of why a placebo group did so well on a larger scale. Europe was instead a good response but incomplete in merit of the the IGF-1 growth factor. This led the EMA to suspend the application for lack of data.